Journée Scientifique 2024

33rd ARTP Annual Meeting - 20 November 2024

 

Metabolic and Immunosuppressive ASPECTS of prostate cancer

Palais des Congrès de Paris - 2 place de la Porte Maillot - 75017 Paris

Téléchargez le plan d'accès au Palais des Congrès / Download access map to Palais des Congrès

Téléchargez les instructions pour Poster / Download Poster Competition Guidelines

Téléchargez le programme en PDF

Téléchargez l'asbract book en PDF 

RAPPEL: nous ne prenons plus d'inscription par mail, l'inscription se fait dorénavant via le site HelloAsso

REMINDER: we no longer accept registrations by e-mail. From now on, you have to register via the HelloAsso website.

 

8:15 a.m

Registration (3rd floor)

 

9:00 a.m.

Welcome

Arnauld Villers, ARTP President

 

 

9:05 a.m

Session I : ARTP & ESUR Laureates 

Chairs : Valério Farfariello & Damien Destouches

 

Vera CONSTÂNCIO (Instituto Português de Oncologia do Porto, Porto, Portugal)

'A novel translational immunocompetent model for investigating prostate cancer bone metastasis'

Delphine MILHAS (Institut de Pharmacologie et de Biologie Structurale, IPBS, Toulouse)

'Role of sex steroids in periprostatic adipose tissue in tumor progression and resistance of prostate cancer to anti-androgen therapy''

Manon BAURES (Institut Necker Enfants Malades, INEM, Paris)

'Mouse LSCmed cells are a model of Club/Hillock Cells of the human prostate'

Darya YANUSHKO (Institut de Génétique et de Biologie Moléculaire et Cellulaire, IGBMC, Strasbourg)

'IL6/JAK/STA3-mediated crosstalk between cancer associated fibroblasts and epithelial cells promotes lineage plasticity and prostate cancer progression'

 

  1. 10:00 a.m

    Coffee Break & Visit of Exhibition Booths

  2.  

  3. 10:20 a.m

    Session II : UNDERSTANDING AND TARGETING PROSTATE CANCER METABOLISM 

    Chairs : Frédéric Bost & Catherine Muller

     

Lisa M. BUTLER (University of Adelaide, Australia)

'Novel approaches to target the prostate cancer lipidome'

 

Anna DUBROVSKA (Helmhotz-Zentrum Dresden-Rossendorf, Germany)

'Development of biomarkers for personalized radiation oncology'

 

Mark A. RUBIN (University of Bern, Switzerland)

'Loss of PI5P4Kα slows the progression of a Pten mutant basal cell model of prostate'

 

 

 

12:00 p.m

Lunch

 

 

 

1:15 p.m

Session III : Clinical Session

Chairs : Charles Dariane & Guilhem Roubaud

 

Pierre-Jean LAMY (Institut d'Analyse Genomique Imagenome, Inovie, Montpellier)

'Circulating biomarkers and treatment response'

 

Paul SARGOS (Institut Bergonié, Bordeaux)

'Classification of risk of recurrence after local treatment'

Davis TAIEB(Assistance Publique - Hôpitaux de Marseille)

'Targeted internal radiotherapy for CRPC: the potential of combination therapeutic approaches'

 

2:20 p.m

Coffee Break & Visit of Exhibition Booths

 

 

2:45 p.m.

Session IV : The immunosuppressive mechanisms at play in prosTate cancer

Chairs : Vincent Goffin & Gilles Laverny

 

Andrea ALIMONTI (Institute of Oncology Research, Bellinzona, Switzerland)

'Role of tumor-infiltrating neutrophils  in prostate cancer'

 

Xin LU (University of Notre Dame, IN, USA)

'Prostate cancer immunosuppression and how to conquer it'

 

David B. SYKES (Harvard Medical School, Boston, MA, USA)

'Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses'

 

 

4:15 p.m.

Session V : Poster Session

Chairs : Edith Bonnelye & Laurent Morel

Les candidats au Prix du Meilleur Poster auront 3 minutes pour présenter leur poster/Candidates for the Best Poster Award will have 3 minutes to present their poster.

Seuls les étudiants de thèse et post-doctorants sont éligibles au prix du meilleur poster/Only thesis students and post-doctoral students are eligible for the best poster award.

 

 

5:30 p.m.

 

Assemblée Générale ARTP

Poster Prize Distribution

Arnauld Villers (Président), Olivier Cuvillier (Trésorier)

5:45 p.m.

End of the Meeting

Sponsors de la journée scientifique 2024

Association Française d'Urologie, La Fondation ARC, Astellas, AstraZeneca/MSD, Bayer, Pierre Fabre Médicament, Viatris Pharma